High-impact alpha-particles therapy sends metastases in remission
New therapies could help in fight against endocrine cancers© Kurhan (stock.xchng)
A joint JRC – University of Heidelberg study on a highly effective therapy for neuro-endocrine cancer received the Young Investigator Award of the Society of Nuclear Medicine (SNM) in San Antonio, USA, at their annual meeting on 4-8 June. The paper “Regional 213Bi-DOTATOC peptide receptor alpha-therapy in patients with neuro-endocrine liver metastases refractory to beta-radiation” is the result of research conducted by a group of scientists of JRC’s Institute for Transuranium Elements (ITU) and fellow colleagues from the University of Heidelberg.
The research offers a hope for patients suffering from neuro-endocrine cancer who do not respond well to standard therapies, such as surgery, chemotherapy and certain types of radiotherapy. Most radiotherapies use beta-emitting particles, but more recently researchers have looked into the use of alpha-emitting particles, which have a very near-range and high-energy effect where administered. The benefit of alpha-therapy is its high cytotoxicity, or ability to kill cancerous cells.